linjc16/ctgov huggingface dataset:
Minimizing Pain Experience In Trigger Finger Steroid Injection.

Study Overview
=================
Brief Summary
-----------------
To study the pain experience of trigger finger steroid injection with 26 gauge needle as compared to 23 gauge needle.

Detailed Description
-----------------
compare pain experience of trigger finger steroid injection between 26 gauge needle and 23 gauge needle.

Official Title
-----------------
Minimizing Pain Experience In Trigger Finger Steroid Injection.

Conditions
-----------------
Trigger Finger

Intervention / Treatment
-----------------
* Device: 26 gauge needle
* Device: 23 gauge needle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age above 18 year old Male or female(non-pregnant) Single trigger finger Clinically diagnosed trigger finger- Green classification Grade I or II No prior surgery to the involved finger Subject is able to provide voluntary, written informed consent Exclusion Criteria: Age less than 18 year old Allergy to lignocaine or corticosteroid Trigger finger with Green classification grade III or IV Previous surgery on the affected finger Any wound, neurovascular injury, or skin disease at injection site Concomitant ipsilateral fingers/wrist/forearm/arm injury Preexisting congenital/acquired deformities of hand (such as rheumatoid arthritis, contracture) Insensate hand

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 26 gauge needle<br>intervention group | Device: 26 gauge needle<br>* smaller gauge needle<br>|
| Active Comparator: 23 gauge needle<br>control group | Device: 23 gauge needle<br>* control group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analog scale-pain | A numerical rating scale of 0 to 100, with 0 meaning no pain and 100 meaning the worst pain | one minute after injection | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
steroid injection, pain, needle gauge, trigger finger
Monitoring Platelet Function During Continuous Hemodialysis

Study Overview
=================
Brief Summary
-----------------
Aim of the study is a description of changes in platelet function during continuous veno-venous hemodialysis or hemofiltration in patients on an intensive care unit using the Multiplate system.

Official Title
-----------------
Changes in Platelet Function During Continuous Veno-venous Hemodialysis Using the Multiplate Device

Conditions
-----------------
Platelet Function

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Need for a continuous renal replacement therapy Platelet Count >100.000/nl Exclusion Criteria: Pregnancy Age <18 years Renal replacement therapy within the 7 days prior to enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dialysis<br>Platelet function will be documented during the first 48 hours of veno-venous hemofiltration using the Multiplate system. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ASPItest | Area under the aggregation curve (AUC) after platelet stimulation with arachidonic acid at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration. | Baseline, 6, 12, 24 and 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ADPtest | Area under the aggregation curve (AUC) after platelet stimulation with adenosine diphosphate at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration. | Baseline, 6, 12, 24 and 48 hours | 
| TRAPtest | Area under the aggregation curve (AUC) after platelet stimulation with thrombin-receptor-activating peptide 6 (TRAP-6) at baseline and 6, 12, 24 and 48 hours after the start of the continuous hemofiltration. | Baseline, 6, 12, 24, 48 hours | 
| CT-INTEM | Clotting time (CT) in the intrinsically activated rotational thrombelastometry (ROTEM) recorded in seconds at baseline and 6, 12, 24 and 48 hours after the start of continuous veno-venous hemofiltration. | Baseline, 6, 12, 24 and 48 hours | 
| MCF-INTEM | Maximum clot firmness (MCF) in the intrinsically activated rotational thrombelastometry (ROTEM) recorded in millimeters at baseline and 6, 12, 24 and 48 hours after the start of continuous veno-venous hemofiltration. | Baseline, 6, 12, 24 and 48hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Platelet function, hemofiltration, Multiplate
Calcium Dobesilate vs Flavonoids for the Treatment of Early Hemorrhoidal Disease

Study Overview
=================
Brief Summary
-----------------
Haemorrhoids are vascular cushions in the anal canal that help in the control of stool. When inflamed they become pathological and may present with protrusion and bleeding. A randomized, triple blind , controlled study will be conducted to compare the efficacy of calcium dobesilate against flavanoids in the management of early haemorrhoidal disease.

Official Title
-----------------
Calcium Dobesilate vs Flavonoids for the Treatment of Early Hemorrhoidal Disease a Randomised Triple Blind Controlled Trial

Conditions
-----------------
Hemorrhoids

Intervention / Treatment
-----------------
* Drug: Flavonoids
* Drug: CDobi


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Grade I and Grade II hemorrhoids Exclusion Criteria: CLD colorectal/ anorectal Malignancy self medication local Quack Hakeem medication pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CDobi<br>Calcium dobesylate is given in this group | Drug: CDobi<br>* Calcium dobesylate is administered<br>* Other names: dobesilate;|
| Active Comparator: Flavono<br>Flavonoids are given in this group | Drug: Flavonoids<br>* Daflon is administered<br>* Other names: Daflon;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of occurrence of rectal bleeding after usage of drug | After the patients will be given the two drugs they will be followed for the frequency of occurrence of rectal bleeding till two weeks | 1 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| regression of hemorrhoids | Patients will under gone per rectal examination and proctoscopy to look for grades of hemorrhoids whether its has decreased or increased. | 1 weeks |
Backwards Examination of the Right Colon: A Back-to-back Study

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the examination of the proximal colon with the retroflexion colonoscopic technique in terms of feasibility and its possible additive contribution in the detection of important lesions, namely polyps and cancers.

Detailed Description
-----------------
The investigators prospectively examined the additional diagnostic yield of right colon examination with colonoscope retroflexion in consecutive, symptomatic and screening - surveillance patients. Right colon was examined in forward-view first and thereafter, retroflexion was performed to re-inspect it.

Official Title
-----------------
Diagnostic Yield of Scope Retroflexion in the Right Colon: A Prospective Cohort Study

Conditions
-----------------
Colon Neoplasms

Intervention / Treatment
-----------------
* Procedure: retroflexion
* Procedure: forward view


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing elective colonoscopy in a Attikon University General Hospital. Exclusion Criteria: patients aged <18 and >80 years; right colectomy; recent abdominalsurgery; multiple diverticula of the right colon; American Society of Anesthesiology (ASA) physical status classification grade IV; inflammatory bowel disease and polyposis syndromes.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: right colon in retroflexion<br>polyp/adenoma detection feasibility | Procedure: retroflexion<br>* examination of the right colon with scope retroflexion<br>|
| Active Comparator: right colon in forward view<br>polyp/adenoma detection | Procedure: forward view<br>* examination of the right colon in forward view<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of additional identified polyps with right colon scope retroflexion |  | one week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in colorectal cancer (CRC) surveillance intervals among screening-surveillance patients | change: YES or NO | one week | 
| Rate of retroflexion-related adverse events. |  | one week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colonoscopy, right colon retroflexion, adenoma detection rate, feasibility, surveillance interval
Pharmacokinetic Comparison of XS003 and Tasigna

Study Overview
=================
Brief Summary
-----------------
The study will assess bioavailability of XS003 given as a single oral dose compared to Tasigna® given as a single oral dose in healthy male subjects.

Detailed Description
-----------------
The study consists of two parts, the first part is composed as a pilot part and compares the bioavailability of single oral doses of XS003 compared to Tasigna® given as single oral dose in healthy male subjects. The second part is a food-effect part which assesses the food effect of a single oral dose of XS003 in healthy male subjects either fed or fasted. The study will also evaluate safety and tolerability of XS003 as secondary objectives.

Official Title
-----------------
A Comparative, Proof of Concept Study, Comprising of a Pilot Phase Bioavailability Study Part and a Randomised, Cross-over Food-effect Study Part of XS003 and Originator in Healthy Male Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: XS003
* Drug: Tasigna


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy males Age 18 to 55 years of age Body mass index (BMI) of 18.0 to 29.0 kg/m2 Laboratory parameters in normal range Exclusion Criteria: Females Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients. History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the investigator. Subject has a QTcF>450 ms based on ECG at screening or a history of additional risk factors for Torsades de Pointe (e.g. hypokalaemia, hypomagnesemia, a family history of long QT syndrome)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: XS003 Dose-level 1<br>Capsule formulation | Drug: XS003<br> <br> * Other names: RightSize Nilotinib;|
| Experimental: XS003 Dose-level 2<br>Capsule formulation | Drug: XS003<br> <br> * Other names: RightSize Nilotinib;|
| Experimental: XS003 Dose-level 3<br>Capsule formulation | Drug: XS003<br> <br> * Other names: RightSize Nilotinib;|
| Experimental: Tasigna<br>Marketed capsule | Drug: Tasigna<br> <br> * Other names: Nilotinib;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioavailability of Nilotinib | Pharmacokinetics measured by Area Under the Curve (AUC) | 3 days |
Ultrasound Study of the Uterine Healing Process After Cesarean Delivery

Study Overview
=================
Brief Summary
-----------------
Our hypothesis is that there is no difference in the healing process in those women who have a one- or two-layer uterine closure at the time of cesarean delivery.

Detailed Description
-----------------
We are recruiting women who are presenting for their first (primary) cesarean delivery. They will be randomized to one- or two-layer myometrial closure at the time of their cesarean delivery. Ultrasound will be used to serially assess the myometrial thickness and myometrial remodeling process.

Official Title
-----------------
Ultrasonographic Assessment of the Uterine Scarring Process Following Closure of the Uterus in One Versus Two Layer Technique.

Conditions
-----------------
Myometrial Remodeling

Intervention / Treatment
-----------------
* Procedure: One- versus two-layer hysterotomy closure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: singleton gestation term pregnancy Kerr uterine incision employed age > 18 Exclusion Criteria: Pain score > 4 Current cesarean delivery for non-reassuring fetal status or other emergent situation (eg. maternal bleeding, etc.) Prior cesarean section Prior uterine surgery Hysterotomy other than Kerr (low transverse) incision in current cesarean Extension of the uterine incision in current cesarean Multifetal pregnancy Maternal diabetes mellitus Maternal connective tissue disorder Uterine malformation Uterine myomas (fibroids) in the anterior lower uterine segment Chorioamnionitis Non-English speaking

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: One- versus two-layer hysterotomy closure|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| myometrial thickness |  |  |
TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam

Study Overview
=================
Brief Summary
-----------------
This study comprises 2 cohorts, and in each cohort, the study will be conducted as an open-label add-on study. The purpose of the study is to investigate the pharmacokinetics of each substrate in concomitant administration of a single dose of the P-glycoprotein substrate digoxin (Cohort A) or the CYP3A4 substrate midazolam (Cohort B) during repeated administration of TRK-700 in healthy adult males.

Official Title
-----------------
TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam in Healthy Adults

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: TRK-700
* Drug: Digoxin
* Drug: Midazolam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Japanese healthy adult males. Subjects with a BMI of at least 18.0 and less than 30.0 at the screening examination and the examination at admission. Exclusion Criteria: Subjects with significant concomitant or historical disease of the metabolism, liver, kidneys, blood, lungs, heart, digestive organs, urinary organs, or nerves, or psychiatric diseases, accompanied by clinical symptoms or with other clinically significant disease, who are unsuitable for participation in this study, in the opinion of the investigators. Subjects who are found by the investigators to have significant clinical abnormality at the screening examination, the examination at admission, or the examination at the day of first administration of Digoxin or Midazolam.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort A<br>TRK-700 + Digoxin | Drug: TRK-700<br>* repeated oral administration<br>Drug: Digoxin<br>* single oral administration with/without TRK-700<br>|
| Experimental: Cohort B<br>TRK-700 + Midazolam | Drug: TRK-700<br>* repeated oral administration<br>Drug: Midazolam<br>* single oral administration with/without TRK-700<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the plasma drug concentration - time curve from administration to the last available concentration measurement of Digoxin and Midazolam(AUClast) |  | Cohort A: up to 72 hours, Cohort B: up to 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Digoxin, TRK-700, PK, Midazolam, Drug-Drug interaction, P-glycoprotein, CYP3A4, MDR1, pharmacokinetics, multidrug resistance 1
Novel Senhance Robotic System in Urologic Surgery: Its Clinical Application and Implication

Study Overview
=================
Brief Summary
-----------------
An observational study to collect data from the participants who received urologic surgeries using the Senhance Robotic system.

Detailed Description
-----------------
This is an observational study and investigators will collect peri-operative demographic data, and short-term outcomes (3-6 months) from the participants who received minimal invasive surgeries using Senhance robotic system in the National Taiwan University Hospital Yunlin Branch, Urology Department. The investigators want to demonstrate if the robotic system is safe and feasible in urologic laparoscopic surgeries. The operation included TEP, radical prostatectomy, radical nephrectomy (nephroureterectomy) , adrenalectomy, radical cystectomy, and ureter surgery et al. up to 2022/12, we had recruited 127 TEP, 83 radical prostatectomies, 17 adrenalectomies, 40 nephrectomies, 29 partial nephrectomies, 13 radical cystectomies and 18 other surgeries, such as ureter surgery

Official Title
-----------------
Novel Senhance Robotic System in Urologic Surgery: Its Clinical Application and Implication

Conditions
-----------------
Urologic Diseases, Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Patients undergo laparoscopic urologic surgeries

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peri-operative complications | Using Clavien-Dindo classification to record the safety outcome | postoperative 30 days | 
| short-term outcome | the short-term outcome was according to a different surgery, such as post-operative 3 months PSA, incontinence rate in radical prostatectomy, | 3-6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Urology, Senhance, Robotic surgical system, Laparoscopic surgery